Compare KOS & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOS | TRAX |
|---|---|---|
| Founded | 2003 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2011 | 2026 |
| Metric | KOS | TRAX |
|---|---|---|
| Price | $2.15 | $51.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $3.12 | ★ $75.17 |
| AVG Volume (30 Days) | ★ 15.9M | 776.1K |
| Earning Date | 11-02-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,288,352,000.00 | N/A |
| Revenue This Year | $39.59 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $15.69 |
| 52 Week High | $3.34 | $54.78 |
| Indicator | KOS | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 35.21 | 68.49 |
| Support Level | $1.92 | $35.11 |
| Resistance Level | $3.08 | N/A |
| Average True Range (ATR) | 0.17 | 3.20 |
| MACD | -0.07 | 0.68 |
| Stochastic Oscillator | 17.86 | 74.05 |
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.